All In Biotech

Drug Trial Radar · NCT01708993

Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.

Last checked: Nov 19, 2026Latest source record: Aug 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

166

Actual

Start

Dec 10, 2012

Primary completion

Jan 26, 2016

Study completion Sep 26, 2018

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Oncolytics Biotech
First posted
Oct 17, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out if giving reolysin in combination with docetaxel or pemetrexed can offer better results than standard therapy with docetaxel or pemetrexed alone.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • Pemetrexed and Reolysin (and safety run-in)Drug

    Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

  • PemetrexedDrug

    Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks

  • Docetaxel and ReolysinDrug

    Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10\^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks

  • DocetaxelDrug

    Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 30 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • BCCA - Abbotsford Centre

    Abbotsford British Columbia, British Columbia, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.